Key result
The mortality benefit of blood pressure-lowering medications persisted during open-label post-trial follow-up (OR 0.85; 95% CI 0.79-0.91; P<0.0001).
Why the study?
Does early intervention with blood pressure-lowering medications persistently reduce overall mortality after the end of randomized clinical trials in patients with hypertension, MI, or LVSD?
Population
132,854 patients with hypertension, myocardial infarction, or left ventricular systolic dysfunction from 18…
Comparison
Blood pressure-lowering medications vs Control group
Design
Meta-analysis
Authors
Loading...
Early BP-lowering confers lasting mortality reduction post-trial; confirms legacy effect in hypertension, MI, and LVSD.
Meta-Analysis (n=132,854)
Does early intervention with blood pressure-lowering medications persistently reduce overall mortality after the end of randomized clinical trials in patients with hypertension, MI, or LVSD?
Odds Ratio: 0.85 (95% CI 0.79–0.91)
p-value: p=<0.0001
The mortality benefit of blood pressure-lowering medications persists even after the end of randomized trials when most patients in both groups receive active therapy, implying that earlier intervention yields better long-term clinical outcomes.
Kostis et al. (2010) conducted a meta-analysis in Hypertension, myocardial infarction, or left ventricular systolic dysfunction (n=132,854). Blood pressure-lowering medications vs. Control was evaluated on Mortality during open-label follow-up (OR 0.85, 95% CI 0.79 to 0.91, p=<0.0001). The mortality benefit of blood pressure-lowering medications persisted during open-label post-trial follow-up (OR 0.85; 95% CI 0.79-0.91; P<0.0001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: